Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week High Following Analyst Upgrade

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s stock price hit a new 52-week high during trading on Tuesday after HC Wainwright raised their price target on the stock from $40.00 to $70.00. HC Wainwright currently has a buy rating on the stock. Oruka Therapeutics traded as high as $65.64 and last traded at $66.1010, with a volume of 417665 shares traded. The stock had previously closed at $61.38.

Several other equities research analysts have also commented on ORKA. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. Leerink Partners upped their price target on Oruka Therapeutics from $58.00 to $86.00 and gave the stock an “outperform” rating in a research note on Monday, March 16th. BTIG Research upped their target price on Oruka Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research report on Monday. UBS Group upped their target price on Oruka Therapeutics from $50.00 to $75.00 and gave the stock a “buy” rating in a research report on Monday, April 6th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $60.00 target price on shares of Oruka Therapeutics in a research report on Friday, March 13th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Oruka Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $74.90.

Insider Activity

In other news, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the sale, the insider owned 33,377 shares of the company’s stock, valued at $1,365,453.07. This represents a 18.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the sale, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at $38,297,861.70. The trade was a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 23,765 shares of company stock valued at $849,575 in the last ninety days. Company insiders own 24.69% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Royal Bank of Canada boosted its holdings in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the last quarter. Kennedy Capital Management LLC boosted its holdings in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after purchasing an additional 420 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after purchasing an additional 904 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $37,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

The stock has a market cap of $3.32 billion, a PE ratio of -36.05 and a beta of -0.54. The business has a fifty day moving average of $40.72 and a 200 day moving average of $33.00.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. On average, equities research analysts expect that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.